George Kaiser Family Foundation Invests $315,000 in Axon Enterprise, Inc $AXON

Key Points

• The George Kaiser Family Foundation acquired 599 shares of Axon Enterprise, Inc (NASDAQ: AXON), valued at approximately $315,000, making it the fund's 26th largest position.
• Analysts remain optimistic about Axon, with various firms setting target prices between $855.00 and $1,000.00 and consensus ratings indicating a "Moderate Buy".
• Axon reported significant growth in revenue, with a 32.6% increase year-over-year and earnings per share of $2.12, exceeding analyst expectations of $1.54.

George Kaiser Family Foundation purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 599 shares of the biotechnology company's stock, valued at approximately $315,000. Axon Enterprise makes up approximately 0.0% of George Kaiser Family Foundation's portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Capital World Investors raised its stake in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after purchasing an additional 841,772 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after purchasing an additional 763,431 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Axon Enterprise by 19.8% in the fourth quarter. Northern Trust Corp now owns 716,926 shares of the biotechnology company's stock worth $426,083,000 after purchasing an additional 118,469 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the completion of the transaction, the insider directly owned 144,538 shares of the company's stock, valued at approximately $108,417,953.80. This represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the transaction, the director directly owned 17,740 shares of the company's stock, valued at $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,695 shares of company stock valued at $40,964,638 in the last quarter. Insiders own 5.70% of the company's stock.

Axon Enterprise Stock Performance

NASDAQ AXON traded down $33.33 on Tuesday, hitting $758.29. 652,727 shares of the stock traded hands, compared to its average volume of 816,362. The business's fifty day moving average is $773.92 and its two-hundred day moving average is $671.99. Axon Enterprise, Inc has a 12 month low of $346.71 and a 12 month high of $885.91. The firm has a market capitalization of $59.53 billion, a price-to-earnings ratio of 187.23, a PEG ratio of 29.05 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period in the prior year, the company earned $1.20 earnings per share. Axon Enterprise's revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AXON shares. Needham & Company LLC set a $870.00 price objective on Axon Enterprise and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Bank of America increased their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. increased their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an "overweight" rating in a research note on Friday, July 11th. Finally, The Goldman Sachs Group increased their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Thirteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $837.69.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.